000538 云南白药
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)9.17012.06810.4467.8227.354
总资产报酬率 ROA (%)6.7628.9027.6445.6815.216
投入资产回报率 ROIC (%)8.16410.5248.8746.5436.141

边际利润分析
销售毛利率 (%)30.85727.89826.50626.32327.150
营业利润率 (%)19.85414.26712.3519.2399.582
息税前利润/营业总收入 (%)19.79913.81111.6568.3158.862
净利润/营业总收入 (%)17.14511.90810.5417.7847.691

收益指标分析
经营活动净收益/利润总额(%)80.83584.90383.614130.329133.101
价值变动净收益/利润总额(%)21.49616.07418.7337.353-25.414
营业外收支净额/利润总额(%)0.273-0.473-0.2590.169-0.101

偿债能力分析
流动比率 (X)2.7372.6562.8512.6313.578
速动比率 (X)2.2822.1662.3452.0422.919
资产负债率 (%)25.73526.54925.80527.74526.560
带息债务/全部投入资本 (%)7.3679.18611.20513.75713.885
股东权益/带息债务 (%)1,220.538959.228770.454607.468602.950
股东权益/负债合计 (%)287.909276.421287.336260.266275.012
利息保障倍数 (X)-182.146-35.545-17.585-8.849-12.480

营运能力分析
应收账款周转天数 (天)86.52989.42887.70080.28253.141
存货周转天数 (天)74.27579.42590.395109.623131.575